Triage strategies and colposcopy referrals in HPV-positive women with low-grade cytology 141 6 1. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 Suppl 5: F88-99. 2. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383(9916): 524-32. 3. Machalek DA, Roberts JM, Garland SM, Thurloe J, Richards A, Chambers I, et al. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. Med J Aust 2019; 211(3): 113-9. 4. Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect 2020; 26(5): 579-83. 5. Loopik DL, Koenjer LM, Siebers AG, Melchers WJG, Bekkers RLM. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program. Am J Obstet Gynecol 2021; 224(2): 200.e1-.e9. 6. RIVM. Monitor bevolkingsonderzoek baarmoederhalskanker 2020.; 2021. 7. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi) genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14(6): 395-405. 8. Durzynska J, Lesniewicz K, Poreba E. Human papillomaviruses in epigenetic regulations. Mutat Res Rev Mutat Res 2017; 772: 36-50. 9. Bierkens M, Hesselink AT, Meijer CJ, Heideman DA, Wisman GB, van der Zee AG, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013; 133(6): 1293-9. 10. De Strooper LM, Meijer CJ, Berkhof J, Hesselink AT, Snijders PJ, Steenbergen RD, et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res (Phila) 2014; 7(12): 1251-7. 11. Vink FJ, Meijer C, Clifford GM, Poljak M, Oštrbenk A, Petry KU, et al. FAM19A4/ miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. Int J Cancer 2020; 147(4): 1215-21. 12. Dick S, Verhoef L, De Strooper LM, Ciocănea-Teodorescu I, Wisman GBA, Meijer CJ, et al. Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. Epigenomics 2020; 12(18): 1569-78. 13. Verhoef L, Bleeker MCG, Polman N, Steenbergen RDM, Meijer C, Melchers WJG, et al. Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPVpositive women: Results from a Dutch primary HPV-based screening cohort. Int J Cancer 2022; 150(3): 440-9. 14. Dippmann C, Schmitz M, Wunsch K, Schütze S, Beer K, Greinke C, et al. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. Clin Epigenetics 2020; 12(1): 171. 15. Bonde J, Floore A, Ejegod D, Vink FJ, Hesselink A, van de Ven PM, et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study. Int J Cancer 2021; 148(2): 396-405. 16. Vink FJ, Lissenberg-Witte BI, Meijer C, Berkhof J, van Kemenade FJ, Siebers AG, et al. FAM19A4/miR124-2 methylation REFERENCES
RkJQdWJsaXNoZXIy MjY0ODMw